Study details
Enrolling now
AT1001 Trial for Long COVID
Massachusetts General Hospital
NCT IDNCT05747534ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
150
Study length
about 3.8 years
Ages
7–50
Locations
2 sites in MA
What this study is about
This trial is testing Larazotide Acetate (AT1001) versus a placebo in people with Long COVID. Participants will take AT1001 or the placebo four times a day for 21 days, and it will last about 1400 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Larazotide Acetate
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Adverse Event Profiling and Time to Symptom Resolution
Secondary: Cytokine profiling, Antigen Testing and Humoral and Cellular Responses
Body systems
Infectious